Last mentioned: Mar 8, 2026
Phase 3 Initiation
Expected launch of the global Phase 3 program for BPL-003 in TRD.
Results Announcement
Company reports 2025 results and confirms Phase 3 timeline.
Fiscal Year End
AtaiBeckley completes 2025 with focused R&D spending on lead assets.
Strategic Investment
atai Life Sciences invests $50M in Beckley Psytech to accelerate BPL-003.
AtaiBeckley has announced its 2025 financial results, highlighted by the upcoming Q2 2026 Phase 3 trial launch for its lead candidate, BPL-003. The intranasal 5-MeO-DMT compound is positioned as a potential blockbuster for treatment-resistant depression with a significantly shorter clinical footprint than existing therapies.
This page surfaces every story mentioning Beckley Psytech across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Beckley Psytech was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |